{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:10:20Z","timestamp":1792285820679,"version":"4.4.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0009734","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000}}],"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Pessoal de N\u00edvel Superior","doi-asserted-by":"crossref","award":["grant number 001"],"award-info":[{"award-number":["grant number 001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["AOS 304335\/2014-2"],"award-info":[{"award-number":["AOS 304335\/2014-2"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["CMVR 313327\/2018-1"],"award-info":[{"award-number":["CMVR 313327\/2018-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment of cutaneous leishmaniasis (CL) remains challenging since the drugs currently used are quite toxic, thus contributing to lethality unrelated to the disease itself but to adverse events (AE). The main objective was to evaluate different treatment regimens with meglumine antimoniate (MA), in a reference center in Rio de Janeiro, Brazil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>\n                      A historical cohort of 592 patients that underwent physical and laboratory examination were enrolled between 2000 and 2017. The outcome measures of effectiveness were epithelialization and complete healing of cutaneous lesions. AE were graded using a standardized scale. Three groups were evaluated: Standard regimen (SR): intramuscular (IM) MA 10\u201320 mg Sb\n                      <jats:sup>5+<\/jats:sup>\n                      \/kg\/day during 20 days (n = 46); Alternative regimen (AR): IM MA 5 mg Sb\n                      <jats:sup>5+<\/jats:sup>\n                      \/kg\/day during 30 days (n = 456); Intralesional route (IL): MA infiltration in the lesion(s) through subcutaneous injections (n = 90). Statistical analysis was performed through Fisher exact and Pearson Chi-square tests, Kruskal-Wallis, Kaplan-Meier and log-rank tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SR, AR and IL showed efficacy of 95.3%, 84.3% and 75.9%, with abandonment rate of 6.5%, 2.4% and 3.4%, respectively. IL patients had more comorbidities (58.9%; p = 0.001), were mostly over 50 years of age (55.6%), and had an evolution time longer than 2 months (65.6%; p = 0.02). Time for epithelialization and complete healing were similar in IL and IM MA groups (p = 0.9 and p = 0.5; respectively). Total AE and moderate to severe AE that frequently led to treatment interruption were more common in SR group, while AR and IL showed less toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions\/Significance<\/jats:title>\n                    <jats:p>AR and IL showed less toxicity and may be good options especially in CL cases with comorbidities, although SR treatment was more effective. IL treatment was an effective and safe strategy, and it may be used as first therapy option as well as a rescue scheme in patients initially treated with other drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0009734","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T05:01:25Z","timestamp":1632459685000},"page":"e0009734","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["An old drug and different ways to treat cutaneous leishmaniasis: Intralesional and intramuscular meglumine antimoniate in a reference center, Rio de Janeiro, Brazil"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-7943","authenticated-orcid":true,"given":"Carla","family":"Oliveira-Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8159-0502","authenticated-orcid":true,"given":"Maria In\u00eas Fernandes","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2714-7139","authenticated-orcid":true,"given":"Liliane de F\u00e1tima Antonio","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica de Camargo Ferreira e","family":"Vasconcellos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-5001","authenticated-orcid":true,"given":"Fatima","family":"Concei\u00e7\u00e3o-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3460-1210","authenticated-orcid":true,"given":"Armando de Oliveira","family":"Schubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Fagundes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia Xavier","family":"de Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliame","family":"Mouta-Confort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1695-1922","authenticated-orcid":true,"given":"Luciana de Freitas Campos","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-9271","authenticated-orcid":true,"given":"Claudia Maria","family":"Valete-Rosalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina da Costa","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9387-8645","authenticated-orcid":true,"given":"Raquel de Vasconcellos Carvalhaes de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2076-8776","authenticated-orcid":true,"given":"Leonardo Pereira","family":"Quintella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-2234","authenticated-orcid":true,"given":"Marcelo Rosandiski","family":"Lyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"pntd.0009734.ref001","first-page":"35","article-title":"Sudden death caused by glucantime","volume":"63","author":"RN Sampaio","year":"1988","journal-title":"An Bras Dermatol"},{"issue":"12","key":"pntd.0009734.ref002","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/j.1365-3156.2009.02408.x","article-title":"Antimony in plasma and skin of patients with cutaneous leishmaniasis- relationship with side effects after treatment with meglumine antimoniate","volume":"14","author":"DB Neves","year":"2009","journal-title":"Trop Med Int Health"},{"issue":"2","key":"pntd.0009734.ref003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"LF Oliveira","year":"2011","journal-title":"Acta Trop"},{"issue":"5","key":"pntd.0009734.ref004","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1590\/S0037-86822012000500011","article-title":"The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil","volume":"45","author":"DS Diniz","year":"2012","journal-title":"Rev Soc Bras Med Trop"},{"issue":"68","key":"pntd.0009734.ref005","first-page":"1","article-title":"Pancreatic toxicity as an adverse effect induced by meglumine antimoniate therapy in a clinical trial for cutaneous leishmaniasis","volume":"58","author":"MR Lyra","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"issue":"6","key":"pntd.0009734.ref006","first-page":"1","article-title":"Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis","volume":"49","author":"MCO Duque","year":"2016","journal-title":"Rev Soc Bras Med Trop"},{"issue":"9","key":"pntd.0009734.ref007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0184777","article-title":"Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review","volume":"12","author":"NC Brito","year":"2017","journal-title":"PLoS One"},{"key":"pntd.0009734.ref008","first-page":"189","volume-title":"Manual de Vigil\u00e2ncia da Leishmaniose Tegumentar Americana","author":"Brazilian Ministry of Health","year":"2017"},{"key":"pntd.0009734.ref009","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-4362.1997.00188.x","article-title":"Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil-an area of Leishmania (V.) braziliensis transmission","volume":"36","author":"MP Oliveira-Neto","year":"1997","journal-title":"Int J Dermatol"},{"issue":"3","key":"pntd.0009734.ref010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1590\/S0037-86822005000300001","article-title":"Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate","volume":"38","author":"AO Schubach","year":"2005","journal-title":"Rev Soc Bras Med Trop"},{"issue":"2","key":"pntd.0009734.ref011","first-page":"52","article-title":"Effectiveness and safety of intralesional treatment with meglumine antimoniate in patients with the cutaneous presentation of American tegumentary leishmaniasis","volume":"43","author":"EC Vasconcellos","year":"2010","journal-title":"Rev Soc Bras Med Trop"},{"issue":"2","key":"pntd.0009734.ref012","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4269\/ajtmh.2012.11-0612","article-title":"Short report: Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic treatment from Rio de Janeiro (2000\u20132006)","volume":"87","author":"ECF Vasconcellos","year":"2012","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"pntd.0009734.ref013","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1590\/0037-8682-0323-2016","article-title":"Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities","volume":"50","author":"MIF Pimentel","year":"2017","journal-title":"Rev Soc Bras Med Trop"},{"issue":"6","key":"pntd.0009734.ref014","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1590\/0037-8682-0464-2017","article-title":"Favorable responses to treatment with 5 mg Sbv\/kg\/day meglumine antimoniate in patients with American tegumentary leishmaniasis acquired in different Brazilian regions","volume":"51","author":"JI Cataldo","year":"2018","journal-title":"Rev Soc Bras Med Trop"},{"issue":"12","key":"pntd.0009734.ref015","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1590\/0074-02760160478","article-title":"Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001\u20132013)","volume":"112","author":"LR Brahim","year":"2017","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"pntd.0009734.ref016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0178592","article-title":"Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil","volume":"12","author":"MN Saheki","year":"2017","journal-title":"PLoS One"},{"key":"pntd.0009734.ref017","author":"Division of AIDS, National Institute of Allergy Infectious Diseases, National Institutes of Health","year":"2017","journal-title":"Division of AIDS table for grading the severity of adult and pediatric adverse events, version 2.1"},{"key":"pntd.0009734.ref018","article-title":"Tratamento e acompanhamento de pacientes com leishmaniose cut\u00e2nea na rede de sa\u00fade","author":"AO Schubach","year":"2019","journal-title":"Academia de Medicina Guanabara Koogan"},{"issue":"1","key":"pntd.0009734.ref019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006141","article-title":"Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation","volume":"12","author":"P Olliaro","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0009734.ref020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1590\/0074-02760160183","article-title":"Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre","volume":"111","author":"RE Silva","year":"2016","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0009734.ref021","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.actatropica.2019.03.007","article-title":"Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit","volume":"193","author":"MCO Duque","year":"2019","journal-title":"Acta Tropica"},{"key":"pntd.0009734.ref022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijpddr.2020.11.002","article-title":"A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis","volume":"14","author":"BC Rodrigues","year":"2020","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"2","key":"pntd.0009734.ref023","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-4632.2008.03417.x","article-title":"Treatment of New World cutaneous leishmaniasis-a systematic review with a meta-analysis","volume":"47","author":"FF Tuon","year":"2008","journal-title":"Int J Dermatol"},{"issue":"6","key":"pntd.0009734.ref024","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4269\/ajtmh.1997.57.651","article-title":"A low dose antimony treatment In 159 patients with American cutaneous leishmaniasis. Extensive follow-up studies (up to 10 years)","volume":"57","author":"MP Oliveira-Neto","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009734.ref025","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/all.12050","article-title":"Delayed allergic skin reactions due to intralesional meglumine antimoniate therapy for cutaneous leishmaniasis","volume":"67","author":"S C\u00f3rdoba","year":"2012","journal-title":"Allergy"},{"issue":"4","key":"pntd.0009734.ref026","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1590\/S0036-46652014000400016","article-title":"Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate","volume":"56","author":"ECF Vasconcellos","year":"2014","journal-title":"Rev Inst Med Trop"},{"issue":"2","key":"pntd.0009734.ref027","first-page":"240","article-title":"Treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate at a primary care unit in Brazil","volume":"6","author":"MCO Duque","year":"2017","journal-title":"Rev Med Saude Brasilia"},{"key":"pntd.0009734.ref028","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.intimp.2008.03.016","article-title":"Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology","volume":"8","author":"KJ Gollob","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"pntd.0009734.ref029","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4269\/ajtmh.2009.80.574","article-title":"Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil","volume":"80","author":"A Unger","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0009734.ref030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nri.2016.72","article-title":"Cutaneous leishmaniasis: immune responses in protection and pathogenesis","volume":"16","author":"P Scott","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"pntd.0009734.ref031","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12879-017-2658-4","article-title":"Clinical and laboratory profiles of patients with early spontaneous healing in cutaneous localized leishmaniasis: a historical cohort study","volume":"17","author":"C Oliveira-Ribeiro","year":"2017","journal-title":"BMC Infect Dis"},{"key":"pntd.0009734.ref032","first-page":"50","article-title":"Concei\u00e7\u00e3o-Siva F. Is the in situ inflammatory reaction an important tool to understand the cellular immune response in American tegumentary leishmaniasis?","volume":"158","author":"FN Morgado","year":"2008","journal-title":"Br J Dermatol"},{"key":"pntd.0009734.ref033","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1365-3024.2009.01188.x","article-title":"Signs of an in situ inflammatory reaction in scars of human American tegumentary leishmaniasis","volume":"32","author":"FN Morgado","year":"2010","journal-title":"Parasite Immunol"},{"key":"pntd.0009734.ref034","author":"K Van Bocxlaer","year":"2021","journal-title":"Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis\u2014Challenges and Opportunities\u2014RSC Medicinal Chemistry"},{"issue":"9","key":"pntd.0009734.ref035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1590\/0074-02760160557","article-title":"Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions","volume":"112","author":"LF Antonio","year":"2017","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"2","key":"pntd.0009734.ref036","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1590\/S0074-02761996000200016","article-title":"High and Low Doses of Antimony (Sbv) in American Cutaneous Leishmaniasis. A Five Years Follow-up Study of 15 Patients","volume":"91","author":"A Oliveira-Neto MP","year":"1996","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"2","key":"pntd.0009734.ref037","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1590\/0074-027601700125","article-title":"Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment","volume":"113","author":"RE Silva","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"9","key":"pntd.0009734.ref038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1590\/0074-02760180200","article-title":"Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial","volume":"113","author":"DB Ramalho","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"pntd.0009734.ref039","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1532-5415.2010.02747.x","article-title":"American tegumentary leishmaniasis in older adults: 44 cases treated with an intermittent low-dose antimonial schedule in Rio de Janeiro, Brazil","volume":"58","author":"ECF Vasconcellos","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"pntd.0009734.ref040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.actatropica.2018.06.001","article-title":"Successful treatment against American cutaneous leishmaniasis by intralesional infiltration of a generic antimonial compound-lidocaine combination. A follow up study","volume":"185","author":"N A\u00f1ez","year":"2018","journal-title":"Acta Tropica"},{"issue":"1","key":"pntd.0009734.ref041","doi-asserted-by":"crossref","first-page":"18","DOI":"10.47993\/gmb.v43i1.13","article-title":"El tratamiento intralesional de Leishmaniasis cut\u00e1nea es seguro frente al riesgo de complicaciones mucosas?","volume":"43","author":"JW Limachi-Choque","year":"2020","journal-title":"Gaceta M\u00e9dica Boliviana"},{"key":"pntd.0009734.ref042","volume-title":"Catagolaci\u00f3n en la Fuente, Organizaci\u00f3n Panamericana de la Salud","author":"PAHO","year":"2013"},{"issue":"3","key":"pntd.0009734.ref043","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1645\/GE-1031R.1","article-title":"Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis","volume":"93","author":"RB Azeredo-Coutinho","year":"2007","journal-title":"J. Parasitol"},{"key":"pntd.0009734.ref044","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.exppara.2008.12.006","article-title":"Leishmania (Viannia) braziliensis genotypes identified in lesions of patients with atypical or typical manifestations of tegumentary leishmaniasis: evaluation by two molecular markers","volume":"121","author":"C Baptista","year":"2009","journal-title":"Exp Parasitol"},{"issue":"7","key":"pntd.0009734.ref045","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1128\/JCM.41.7.3126-3132.2003","article-title":"Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil","volume":"41","author":"E Cupolillo","year":"2003","journal-title":"J Clin Microbiol"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0009734","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009734","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T04:21:24Z","timestamp":1699503684000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009734"}},"subtitle":[],"editor":[{"given":"Gregory","family":"Deye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009734","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]}}}